Brivanib in combination with Notch3 silencing shows potent activity in tumour models.

Published on Feb 15, 2019in British Journal of Cancer5.791
· DOI :10.1038/S41416-018-0375-4
Catia Giovannini19
Estimated H-index: 19
(UNIBO: University of Bologna),
Anna Maria Salzano22
Estimated H-index: 22
(National Research Council)
+ 9 AuthorsLaura Gramantieri41
Estimated H-index: 41
Sources
Abstract
Sorafenib is the first targeted agent proven to improve survival of patients with advanced hepatocellular carcinoma (HCC) and it has been used in first line treatments with heterogeneous response across patients. Most of the promising agents evaluated in first-line or second-line phase III trials for HCC failed to improve patient survival. The absence of molecular characterisation, including the identification of pathways driving resistance might be responsible for these disappointing results. 2D DIGE and MS analyses were used to reveal proteomic signatures resulting from Notch3 inhibition in HepG2 cells, combined with brivanib treatment. The therapeutic potential of Notch3 inhibition combined with brivanib treatment was also demonstrated in a rat model of HCC and in cell lines derived from different human cancers. Using a proteomic approach, we have shown that Notch3 is strongly involved in brivanib resistance through a p53-dependent regulation of enzymes of the tricarboxylic acid (TCA), both in vitro and in vivo. We have demonstrated that regulation of the TCA cycle is a common mechanism in different human cancers, suggesting that Notch3 inhibitors combined with brivanib treatment may represent a strong formulation for the treatment of HCC as well as Notch3-driven cancers.
📖 Papers frequently viewed together
2014
2 Authors (Chuan Yin, Wei-Fen Xie)
8 Citations
51 Citations
52 Citations
References48
Newest
#1Alexey A. Leontovich (Mayo Clinic)H-Index: 28
#2Mohammad Jalalirad (Mayo Clinic)H-Index: 4
Last. Antonino B. D'Assoro (Mayo Clinic)H-Index: 20
view all 23 authors...
Development of distant metastases involves a complex multistep biological process termed the invasion-metastasis cascade, which includes dissemination of cancer cells from the primary tumor to secondary organs. NOTCH developmental signaling plays a critical role in promoting epithelial-to-mesenchymal transition, tumor stemness, and metastasis. Although all four NOTCH receptors show oncogenic properties, the unique role of each of these receptors in the sequential stepwise events that typify the ...
31 CitationsSource
#1G. Diluvio (Sapienza University of Rome)H-Index: 2
#2Francesca Del Gaudio (KI: Karolinska Institutet)H-Index: 4
Last. Saula ChecquoloH-Index: 19
view all 15 authors...
Notch dysregulation has been implicated in numerous tumors, including triple-negative breast cancer (TNBC), which is the breast cancer subtype with the worst clinical outcome. However, the importance of individual receptors in TNBC and their specific mechanism of action remain to be elucidated, even if recent findings suggested a specific role of activated-Notch3 in a subset of TNBCs. Epidermal growth factor receptor (EGFR) is overexpressed in TNBCs but the use of anti-EGFR agents (including tyr...
25 CitationsSource
#1Nicole M. Anderson (UPenn: University of Pennsylvania)H-Index: 2
#1Nicole M. Anderson (UPenn: University of Pennsylvania)H-Index: 10
Last. Hui Feng (BU: Boston University)H-Index: 20
view all 4 authors...
The tricarboxylic acid (TCA) cycle is a central route for oxidative phosphorylation in cells, and fulfills their bioenergetic, biosynthetic, and redox balance requirements. Despite early dogma that cancer cells bypass the TCA cycle and primarily utilize aerobic glycolysis, emerging evidence demonstrates that certain cancer cells, especially those with deregulated oncogene and tumor suppressor expression, rely heavily on the TCA cycle for energy production and macromolecule synthesis. As the fiel...
151 CitationsSource
#1Dong WangH-Index: 8
#1Dong WangH-Index: 2
Last. Suling LiuH-Index: 37
view all 14 authors...
IL6 blockade potentiates the anti-tumor effects of γ -secretase inhibitors in Notch3-expressing breast cancer
24 CitationsSource
#1Catia GiovanniniH-Index: 19
#2Michele BaglioniH-Index: 11
Last. Laura GramantieriH-Index: 41
view all 6 authors...
Scientific Reports 7: Article number: 44685; published online: 21 March 2017; updated: 22 December 2017. The original title of our paper was inaccurate in referring to ‘Venom from Cuban Blue Scorpion’ and did not accurately reflect that we investigated the effects of the commercially-available product Vidatox 30 CH on hepatocellular carcinoma.
1 CitationsSource
#1Jorge S. Burns (Politehnica University of Bucharest)H-Index: 6
#2Gina MandaH-Index: 16
Focus on the Warburg effect, initially descriptive of increased glycolysis in cancer cells, has served to illuminate mitochondrial function in many other pathologies. This review explores our current understanding of the Warburg effect’s role in cancer, diabetes and ageing. We highlight how it can be regulated through a chain of oncogenic events, as a chosen response to impaired glucose metabolism or by chance acquisition of genetic changes associated with ageing. Such chain, choice or chance pe...
72 CitationsSource
#1Wanhu Zhu (Fudan University)H-Index: 2
#2Qing Liang (Fudan University)H-Index: 3
Last. Guangchun Sun (Fudan University)H-Index: 3
view all 6 authors...
Sorafenib is currently the only approved first-line targeted drug against advanced hepatocellular carcinoma (HCC). However, unsatisfactory efficacy and resistance of sorafenib raises the urgent need to develop more effective therapeutic strategies for HCC. Here, we evaluated the effects of combination of histone deacetylase inhibitor Valproic acid (VPA) and sorafenib in HCC both in vitro and in vivo. Co-treatment of sorafenib and VPA synergistically inhibited HCC cell viability, induced cell apo...
14 Citations
#1Hyoung Kyu Kim (Inje University)H-Index: 26
#2Yeon Hee Noh (Inje University)H-Index: 3
Last. Jin Han (Inje University)H-Index: 6
view all 7 authors...
Abstract Mitochondria are essential intracellular organelles that regulate energy metabolism, cell death, and signaling pathways that are important for cell proliferation and differentiation. Therefore, mitochondria are fundamentally implicated in cancer biology, including initiation, growth, metastasis, relapse, and acquired drug resistance. Based on these implications, mitochondria have been proposed as a major therapeutic target for cancer treatment. In addition to classical view of mitochond...
30 CitationsSource
#1Ioannis A. Ziogas (A.U.Th.: Aristotle University of Thessaloniki)H-Index: 8
#2Georgios Tsoulfas (A.U.Th.: Aristotle University of Thessaloniki)H-Index: 17
: Hepatocellular carcinoma (HCC) is one of the most common malignant diseases worldwide and comes third in cancer-related mortality. Although there is a broad spectrum of treatment options to choose from, only a few patients are eligible candidates to receive a curative therapy according to their stage of disease, and thus palliative treatment is implemented in the majority of the patients suffering from liver cancer. Sorafenib, a multikinase inhibitor, is the only currently approved agent for s...
26 CitationsSource
#1Jessica FlöterH-Index: 4
#2Irem KaymakH-Index: 3
Last. Almut SchulzeH-Index: 47
view all 3 authors...
Metabolic reprogramming in cancer cells is controlled by the activation of multiple oncogenic signalling pathways in order to promote macromolecule biosynthesis during rapid proliferation. Cancer cells also need to adapt their metabolism to survive and multiply under the metabolically compromised conditions provided by the tumour microenvironment. The tumour suppressor p53 interacts with the metabolic network at multiple nodes, mostly to reduce anabolic metabolism and promote preservation of cel...
38 CitationsSource
Cited By3
Newest
#1Zahra Farzaneh (Royan Institute)H-Index: 7
#2Massoud Vosough (Royan Institute)H-Index: 15
Last. Maryam Farzaneh (Ahvaz Jundishapur University of Medical Sciences)H-Index: 12
view all 4 authors...
Hepatocellular carcinoma (HCC) is the second leading cause of death due to cancer. Although there are different treatment options, these strategies are not efficient in terms of restricting the tumor cell's proliferation and metastasis. The liver tumor microenvironment contains the non-parenchymal cells with supportive or inhibitory effects on the cancerous phenotype of HCC. Several signaling pathways are dis-regulated in HCC and cause uncontrolled cell propagation, metastasis, and recurrence of...
1 CitationsSource
#1Gillian Moore (RCSI: Royal College of Surgeons in Ireland)H-Index: 6
#2Stephanie Annett (RCSI: Royal College of Surgeons in Ireland)H-Index: 7
Last. Tracy Robson (RCSI: Royal College of Surgeons in Ireland)H-Index: 34
view all 4 authors...
Evolutionarily conserved Notch plays a critical role in embryonic development and cellular self-renewal. It has both tumour suppressor and oncogenic activity, the latter of which is widely described. Notch-activating mutations are associated with haematological malignancies and several solid tumours including breast, lung and adenoid cystic carcinoma. Moreover, upregulation of Notch receptors and ligands and aberrant Notch signalling is frequently observed in cancer. It is involved in cancer hal...
20 CitationsSource
#1Francesca FornariH-Index: 24
#2Laura GramantieriH-Index: 41
Last. Catia GiovanniniH-Index: 19
view all 7 authors...
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality. Molecular heterogeneity and absence of biomarkers for patient allocation to the best therapeutic option contribute to poor prognosis of advanced stages. Aberrant microRNA (miRNA) expression is associated with HCC development and progression and influences drug resistance. Therefore, miRNAs have been assayed as putative biomarkers and therapeutic targets. MiRNA-based therapeutic approaches demonstrated safety ...
10 CitationsSource